Advanced search
1 file | 1.08 MB Add to list

Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma

Nora Sundahl (UGent) , Gillian Vandekerkhove, Karel Decaestecker (UGent) , Annabel Meireson (UGent) , Pieter De Visschere (UGent) , Valerie Fonteyne (UGent) , Daan De Maeseneer (UGent) , Dries Reynders (UGent) , Els Goetghebeur (UGent) , Jo Van Dorpe (UGent) , et al.
(2019) EUROPEAN UROLOGY. 75(5). p.707-711
Author
Organization
Keywords
Metastatic urothelial carcinoma, Checkpoint inhibitor, Immunotherapy, Stereotactic body radiotherapy, Circulating tumor DNA, Precision oncology

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.08 MB

Citation

Please use this url to cite or link to this publication:

MLA
Sundahl, Nora et al. “Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.” EUROPEAN UROLOGY 75.5 (2019): 707–711. Print.
APA
Sundahl, N., Vandekerkhove, G., Decaestecker, K., Meireson, A., De Visschere, P., Fonteyne, V., De Maeseneer, D., et al. (2019). Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. EUROPEAN UROLOGY, 75(5), 707–711.
Chicago author-date
Sundahl, Nora, Gillian Vandekerkhove, Karel Decaestecker, Annabel Meireson, Pieter De Visschere, Valerie Fonteyne, Daan De Maeseneer, et al. 2019. “Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.” European Urology 75 (5): 707–711.
Chicago author-date (all authors)
Sundahl, Nora, Gillian Vandekerkhove, Karel Decaestecker, Annabel Meireson, Pieter De Visschere, Valerie Fonteyne, Daan De Maeseneer, Dries Reynders, Els Goetghebeur, Jo Van Dorpe, Sofie Verbeke, Matti Annala, Lieve Brochez, Kim Van der Eecken, Alexander W Wyatt, Sylvie Rottey, and Piet Ost. 2019. “Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.” European Urology 75 (5): 707–711.
Vancouver
1.
Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, De Visschere P, Fonteyne V, et al. Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. EUROPEAN UROLOGY. 2019;75(5):707–11.
IEEE
[1]
N. Sundahl et al., “Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma,” EUROPEAN UROLOGY, vol. 75, no. 5, pp. 707–711, 2019.
@article{8600812,
  author       = {Sundahl, Nora and Vandekerkhove, Gillian and Decaestecker, Karel and Meireson, Annabel and De Visschere, Pieter and Fonteyne, Valerie and De Maeseneer, Daan and Reynders, Dries and Goetghebeur, Els and Van Dorpe, Jo and Verbeke, Sofie and Annala, Matti and Brochez, Lieve and Van der Eecken, Kim and Wyatt, Alexander W and Rottey, Sylvie and Ost, Piet},
  issn         = {0302-2838},
  journal      = {EUROPEAN UROLOGY},
  keywords     = {Metastatic urothelial carcinoma,Checkpoint inhibitor,Immunotherapy,Stereotactic body radiotherapy,Circulating tumor DNA,Precision oncology},
  language     = {eng},
  number       = {5},
  pages        = {707--711},
  title        = {Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma},
  url          = {http://dx.doi.org/10.1016/j.eururo.2019.01.009},
  volume       = {75},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: